Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs

Autor: Luke A. Hyder, Michelle A. Lowes, Leanne M. Johnson-Huang, Katherine C. Pierson, Cara A. Pensabene, Mayte Suárez-Fariñas, Mary Sullivan-Whalen, Inna Cueto, Tim Lentini, James G. Krueger, Patricia Gilleaudeau, Kejal R. Shah, Toyoko Kikuchi, Artemis Khatcherian
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Male
Myeloid
T-Lymphocytes
Efalizumab
030207 dermatology & venereal diseases
0302 clinical medicine
Immunophenotyping
Cell Movement
Recurrence
Cytotoxic T cell
Myeloid Cells
CD11a Antigen
0303 health sciences
Multidisciplinary
Antibodies
Monoclonal

hemic and immune systems
Genomics
3. Good health
medicine.anatomical_structure
Medicine
Tumor necrosis factor alpha
Female
medicine.drug
Research Article
CD14
Immune Cells
Science
Immunology
chemical and pharmacologic phenomena
CD11a
Biology
Antibodies
Monoclonal
Humanized

Autoimmune Diseases
03 medical and health sciences
Genome Analysis Tools
Psoriasis
medicine
Humans
030304 developmental biology
Inflammation
Computational Biology
Dendritic Cells
medicine.disease
Immune System
Cell Migration Inhibition
Immunologic Techniques
Clinical Immunology
Transcriptome
Zdroj: PLoS ONE, Vol 7, Iss 2, p e30308 (2012)
PLoS ONE
ISSN: 1932-6203
Popis: UnlabelledTo understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3(+) T cells, neutrophils, CD11c(+) and CD83(+) myeloid dendritic cells (DCs), but no increase in CD1c(+) resident myeloid DCs. In relapsed lesions, there were many CD11c(+)CD1c(-), inflammatory myeloid DCs identified by TNFSF10/TRAIL, TNF, and iNOS. CD11c(+) cells in relapsed lesions co-expressed CD14 and CD16 in situ. Efalizumab induced an improvement in many psoriasis genes, and during relapse, the majority of these genes reversed back to a lesional state. Gene Set Enrichment Analysis (GSEA) of the transcriptome of relapsed tissue showed that many of the gene sets known to be present in psoriasis were also highly enriched in relapse. Hence, on ceasing efalizumab, T cells and myeloid cells rapidly enter the skin to cause classic psoriasis.Trial registrationClinicaltrials.gov NCT00115076.
Databáze: OpenAIRE